Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report.

Valizada H, Zilbermint M

Cureus20 Jul 2026

PMID42622003 (opens in a new tab)PMCIDPMC13489215 (opens in a new tab)DOI10.7759/cureus.113026 (opens in a new tab)PepBankPUB-42622003
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the treatment of obesity and diabetes mellitus because of their efficacy in weight reduction, glycemic control, and overall metabolic benefits. Gastrointestinal adverse events are among the most frequently reported side effects associated with these agents and are typically transient, occurring predominantly during dose escalation. However, severe gastrointestinal intolerance requiring hospitalization has rarely been reported. We present the case of a 51-year-old woman with obesity, hypertension, hyperlipidemia, and anxiety who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week treatment interruption during Ramadan. The patient had previously tolerated semaglutide therapy for approximately one year, with successful weight loss. Laboratory evaluation revealed significant electrolyte abnormalities, while contrast-enhanced abdominal and pelvic CT showed no acute pathology. The patient was managed with supportive treatment, including intravenous hydration, electrolyte replacement, antiemetics, and dietary modifications. She was discharged after four days of hospitalization, and cautious semaglutide reinitiation with dose escalation was planned after two weeks. This case highlights an important educational opportunity during Ramadan counseling, as patients receiving GLP-1 receptor agonists should generally be advised not to discontinue therapy solely because of daytime fasting unless clinically indicated. If treatment interruption occurs for a prolonged period, cautious reinitiation beginning at a lower dose with gradual dose escalation should be considered to minimize gastrointestinal adverse events. Careful dose re-titration after extended lapses in therapy may help reduce this risk. Further studies are needed to establish evidence-based recommendations for semaglutide reinitiation after prolonged treatment interruptions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 51-year-old woman with obesity, severe nausea, vomiting and diarrhea developed one day after restarting semaglutide 2.4 mg following a five-week interruption.

    In plain wordsOne woman had severe nausea, vomiting and diarrhea a day after restarting semaglutide following a five-week break.

    Peptide
    Semaglutide
    Outcome
    IncreaseSevere nausea, vomiting and diarrhoea after restarting semaglutide
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    We present the case of a 51-year-old woman with obesity, hypertension, hyperlipidemia, and anxiety who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week treatment interruption during Ramadan.
  2. 02HumanCase report or seriesSafety outcome

    In a 51-year-old woman with severe gastrointestinal intolerance after restarting semaglutide, laboratory evaluation showed significant electrolyte abnormalities.

    In plain wordsOne woman who restarted semaglutide and became very sick showed significant salt and mineral imbalances in blood tests.

    Peptide
    Semaglutide
    Outcome
    IncreaseElectrolyte abnormalities
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation revealed significant electrolyte abnormalities
    1 context sentence
    Summary · context
    We present the case of a 51-year-old woman with obesity, hypertension, hyperlipidemia, and anxiety who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week treatment interruption during Ramadan.
  3. 03HumanCase report or seriesSafety outcome

    In a 51-year-old woman, severe gastrointestinal intolerance after restarting semaglutide required four days of hospitalization.

    In plain wordsOne woman needed four days in hospital after severe stomach and gut symptoms when she restarted semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseHospitalization for gastrointestinal intolerance
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    2.4 mg · four days of hospitalizationAs given in this study (human).

    Source sentences

    Summary
    She was discharged after four days of hospitalization
    1 context sentence
    Summary · context
    We present the case of a 51-year-old woman with obesity, hypertension, hyperlipidemia, and anxiety who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week treatment interruption during Ramadan.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 51-year-old woman with obesity, semaglutide therapy for approximately one year was tolerated and led to successful weight loss before the interruption.

    In plain wordsOne woman with obesity took semaglutide for about a year before the break, tolerated it well and lost weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss during prior semaglutide therapy
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · approximately one yearAs given in this study (human).

    Source sentences

    Summary
    The patient had previously tolerated semaglutide therapy for approximately one year, with successful weight loss.
    1 context sentence
    Summary · context
    We present the case of a 51-year-old woman with obesity, hypertension, hyperlipidemia, and anxiety who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week treatment interruption during Ramadan.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.